Dossier assessment

Serplulimab (oesophageal squamous cell carcinoma) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A26-90
Last updated

Report documents

  1. Extract of dossier assessment

    Serplulimab (oesophageal squamous cell carcinoma) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 220 kB, DE, not accessible
  2. Dossier assessment

    Serplulimab (oesophageal squamous cell carcinoma) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 1 MB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A26-90

Dossier assessment

Indication:

Adults with unresectable, locally advanced, recurrent or metastatic oesophageal squamous cell carcinoma that cannot be treated with curative intent

Result of dossier assessment:
  • Patients whose tumours have a combined positive score (CPS)≥5 and also a tumour cell programmed cell death-ligand 1 (PD-L1) expression of ≥1%, or whose tumours have a CPS≥10 regardless of tumour cell PD-L1 expression; first-line treatment: added benefit not proven
  • Patients whose tumours have a CPS between ≥5 and <10 and also no tumour cell PD-L1 expression of ≥1%; first-line treatment: added benefit not proven

Project details

Project no.
A26-90
Commission
Commission awarded on 23.06.2026 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A26-90

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form